Soumyajit Roy1,2,3, Svetlana Kuznetsova4, Kundan Thind2,4, Petra Grendarova2,3, Nicolas Ploquin2,4, Richie S Sinha2,3. 1. Radiation Medicine Program, Ottawa Hospital Cancer Center, University of Ottawa, Ontario, Canada†. 2. Department of Oncology, University of Calgary, Calgary, Alberta, Canada. 3. Division of Radiation Oncology, Tom Baker Cancer Center, Alberta Health Services, 1331-29th Street NW, Calgary, Alberta, T2N 4N2, Canada. 4. Division of Medical Physics, Tom Baker Cancer Center, Alberta Health Services, 1331-29th Street NW, Calgary, Alberta, T2N 4N2, Canada.
Abstract
OBJECTIVES: We evaluated the dosimetric and radiobiological impact of abdominal compression (AC) on nearby gastrointestinal critical structures (GI-CS) and reported toxicities of patients treated with non-hepatic abdominal stereotactic body radiotherapy (SBRT). METHODS: Two sets of CT scans, planning scans with AC and pre-treatment diagnostic scans without AC (non-AC) were compared for patients treated with a prescription dose to planning target volume (PTV) ≥25 Gy/5-fractions at a single institution. Target volumes were delineated on both sets of scans and PTV was expanded isotropically by 2 cm (PTV+2) and 4 cm (PTV+4). All GI-CS were summated to create a composite CS (GI-lumen). Rigid registration of AC and non-AC scans was done using Velocity AI (Varian Medical Systems) to obtain dose distribution information. Lymann-Probit and logit models were used for radiobiological calculations. Toxicity scores were obtained from prospectively collected clinical data. RESULTS: A total of 12 patients were included. Mean PTV volumes were 190.3cc and 196.4cc with AC and non-AC (p=0.95). Significant improvement in V30 of GI-lumen was seen with AC (0.11cc vs. 4.97cc, p=0.04). There were no differences in the normal tissue complication probabilities of the individual GI-CS or the summary indices except a notable trend towards better NTCP for small bowel late effects with AC (0.21% vs. 2.45%; p=0.055). Three patients had acute grade-1 anorexia, one patient had acute grade-2 gastritis. There was no grade ≥3 GI toxicity. At a median follow-up of 2.6 years, total of 8/12 (66.7%) patients developed local recurrence of whom 4 (33.3%) had isolated local recurrence. CONCLUSION: Use of AC did not result in any dosimetric or radiobiological inferiority for GI-CS. The current cohort completed their treatment with minimal toxicity.
OBJECTIVES: We evaluated the dosimetric and radiobiological impact of abdominal compression (AC) on nearby gastrointestinal critical structures (GI-CS) and reported toxicities of patients treated with non-hepatic abdominal stereotactic body radiotherapy (SBRT). METHODS: Two sets of CT scans, planning scans with AC and pre-treatment diagnostic scans without AC (non-AC) were compared for patients treated with a prescription dose to planning target volume (PTV) ≥25 Gy/5-fractions at a single institution. Target volumes were delineated on both sets of scans and PTV was expanded isotropically by 2 cm (PTV+2) and 4 cm (PTV+4). All GI-CS were summated to create a composite CS (GI-lumen). Rigid registration of AC and non-AC scans was done using Velocity AI (Varian Medical Systems) to obtain dose distribution information. Lymann-Probit and logit models were used for radiobiological calculations. Toxicity scores were obtained from prospectively collected clinical data. RESULTS: A total of 12 patients were included. Mean PTV volumes were 190.3cc and 196.4cc with AC and non-AC (p=0.95). Significant improvement in V30 of GI-lumen was seen with AC (0.11cc vs. 4.97cc, p=0.04). There were no differences in the normal tissue complication probabilities of the individual GI-CS or the summary indices except a notable trend towards better NTCP for small bowel late effects with AC (0.21% vs. 2.45%; p=0.055). Three patients had acute grade-1 anorexia, one patient had acute grade-2 gastritis. There was no grade ≥3 GI toxicity. At a median follow-up of 2.6 years, total of 8/12 (66.7%) patients developed local recurrence of whom 4 (33.3%) had isolated local recurrence. CONCLUSION: Use of AC did not result in any dosimetric or radiobiological inferiority for GI-CS. The current cohort completed their treatment with minimal toxicity.
Authors: David J Brenner; Rainer K Sachs; Lester J Peters; H Rodney Withers; Eric J Hall Journal: Int J Radiat Oncol Biol Phys Date: 2012-03-15 Impact factor: 7.038
Authors: Louis Potters; Michael Steinberg; Christopher Rose; Robert Timmerman; Samuel Ryu; James M Hevezi; James Welsh; Minesh Mehta; David A Larson; Nora A Janjan Journal: Int J Radiat Oncol Biol Phys Date: 2004-11-15 Impact factor: 7.038
Authors: Michael Velec; Joanne L Moseley; Cynthia L Eccles; Tim Craig; Michael B Sharpe; Laura A Dawson; Kristy K Brock Journal: Int J Radiat Oncol Biol Phys Date: 2010-08-21 Impact factor: 7.038
Authors: S Gwynne; L Wills; G Joseph; G John; J Staffurth; C Hurt; S Mukherjee Journal: Clin Oncol (R Coll Radiol) Date: 2009-09-04 Impact factor: 4.126
Authors: John H Heinzerling; John F Anderson; Lech Papiez; Thomas Boike; Stanley Chien; Geoffrey Zhang; Ramzi Abdulrahman; Robert Timmerman Journal: Int J Radiat Oncol Biol Phys Date: 2008-04-01 Impact factor: 7.038